Between the Lines: Expanding Treatment Options in Retina Diseases with Biosimilars
home / video-series / between-the-lines-expanding-treatment-options-in-retina-diseases-with-biosimilars
Expert retina specialists discuss the efficacy and safety data of the ranibizumab biosimilar, SB11, and explore the practical implications of biosimilars in the broader real-world context.
